Purpose: The eighth edition of the TNM classification of malignant tumors for the first time includes an official staging system for thymic epithelial tumors (TETs) recognized by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC). Staging is critical for the management of TETs, and determining stage accurately from imaging has the potential to improve clinical outcomes. We examine preoperative computed tomography (CT) characteristics of TETs associated with AJCC/UICC pathologic TNM stage.
T hymic epithelial tumors (TETs) are rare tumors of the prevascular (anterior) mediastinum. 1 For the first time, there is an official staging system for TETs recognized in the 2017 eighth edition of the TNM Classification of Malignant Tumors by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC). 2 Historically, many staging systems have been used for TETs, including both non-TNM based and TNM based. 3 Many of these were based on small sample sizes at single institutions and have never been validated. The Masaoka-Koga staging system is still the most commonly used and the International Thymic Malignancy Interest Group (ITMIG) had established it as the unified staging system (Table 1) for use until publication of the eighth edition of AJCC/UICC staging manuals. 4 There are limitations of the Masaoka-Koga staging system, including lack of survival difference between stages I and II disease, stage III disease involving invasion of a large range of structures, and a predominantly pathologic staging system that is difficult to apply to clinical staging. 5, 6 The IASLC (International Association for the Study of Lung Cancer)/ITMIG staging system, which has been included in the official eighth edition of AJCC/UICC staging manuals, is based on TNM descriptors ( Table 1 ). The T stage is derived from Masaoka-Koga staging and is defined by the highest level of invasion of ≥ 1 structures, with an overall decreased emphasis on tumor encapsulation. 7 The N stage (N1, N2) defines lymph node regions on the basis of a lymph node map. 8 The M stage separates pleural or pericardial nodules (M1a) from pulmonary nodules or distant metastases (M1b). 9 Stage groups I to IIIB are decided by the T component, whereas stage IVA/B groups are decided by the N and/ or M component. 5 Staging is critical for the management of TETs. 10, 11 multimodality approach, and most stage IVA/B TETs are managed with systemic chemotherapy. The imaging modality of choice for the workup of TETs is computed tomography (CT) scan of the thorax with intravenous contrast. CT is important in differentiating TETs from other malignant and nonmalignant conditions, identifying the need for pretreatment biopsy, and assessing surgical resectability. The ability to determine stage on the basis of CT characteristics could improve outcomes by identifying patients with advanced disease (ie, Masaoka-Koga stage III or higher) who would benefit from neoadjuvant therapy. There have been retrospective studies examining CT characteristics and their association with Masaoka and Masaoka-Koga staging 12 along with completeness of resection 13 and World Health Organization (WHO) histology subtype. 14 However, to our knowledge, CT characteristics have never been studied in relation to the now official IASLC/ITMIG staging for TETs. Therefore, we performed a retrospective review with a primary objective to analyze CT characteristics associated with IASLC/ITMIG pathologic stage.
MATERIALS AND METHODS

Inclusion Criteria
This study was performed under an IRB-approved protocol, including an approval for waiver of consent for retrospective chart reviews. All investigators were in Health Insurance Portability and Accountability Act compliance. We used the Stanford Cancer Institute Research Database to retrospectively identify thymic malignancies by ICD-9 diagnostic codes and pathology reports. Patients were included who fit all the following criteria: (1) had a diagnosis of TET (thymoma, thymic carcinoma, or neuroendocrine tumor of thymus), (2) had their primary curative intent surgery performed at Stanford University, and (3) had available preoperative CT imaging for review. For patients with > 1 preoperative CT, the most recent was used. For patients who received neoadjuvant chemotherapy, the restaging imaging was reviewed to account for the possibility of "downstaging."
Standard Report Terms
There was no standard protocol for CT imaging, as 43% of studies were provided by outside institutions. The majority of studies were assessed with intravenous contrast (n = 47; 87%). CT studies were reconstructed at variable section thickness: 1 to 2.5 mm, n = 33; 3 to 5 mm, n = 20; and 7 mm, n = 1. A chest radiologist reviewed the CT and was blinded to clinicopathologic data. Images were analyzed and reported as per ITMIG-defined standard report terms for chest CT reports of anterior mediastinal masses suspicious for thymoma. 15 The characteristics evaluated included size (longest dimension on axial slice), contour (smooth vs. lobulated), internal density (homogeneous vs. heterogeneous), and presence of calcification, infiltration of mediastinal fat, abutment of ≥ 50% of mediastinal vessels, vascular endoluminal invasion, abutment of adjacent mediastinal structures, invasion of adjacent mediastinal structures, elevated hemidiaphragm, pleural effusion, Clinical characteristics were collected along with diagnosis and treatment parameters. Pathologic staging was assessed by the IASLC/ITMIG staging system (referred to as TNM hereafter) 5, 7, 9 as well as by the Masaoka-Koga staging system with ITMIG clarifications 4 (Table 1) . Histology was classified by the 2004 WHO classification. 16 We performed a retrospective chart review of pathology reports and operative reports to examine staging and WHO subtype. In cases wherein it was not clear, a blinded pathologist carried out the review. Of note, lymph node dissections were not routinely performed, and only 43% of patients had at least 1 evaluable lymph node. Therefore, the majority of cases were classified as N0 unless there was definitive nodal involvement. Resection status was classified as R0 (complete), R1 (microscopic incomplete), and R2 (macroscopic incomplete).
Statistical Analysis
All CT variables except pulmonary nodules (all considered nonspecific) and extrathoracic metastases (none identified in the cohort) were included in the analyses. Standard tests for comparing variables were used: Wilcoxon test for continuous variables and the Fisher's exact test for binary or ordinal variables. A proportional odds regression model was used to determine univariate associations of CT characteristics with ordered categories of TNM stage, Masaoka-Koga stage, WHO histology, and resection status. A Lasso-regularized multivariate model including all CT variables was used to determine a scoring system associated with stage in our cohort. The model adds weights to each feature depending on how much it contributes to the prediction of TNM stage (I vs. II to IV), T stage (T1 vs. T2 to T4), and Masaoka-Koga stage (I to II vs. III to IV). The Kaplan-Meier method was used to determine event-free survival (time of pathologic diagnosis to time of death or recurrence, whichever came earlier) and overall survival (time of pathologic diagnosis to time of death). A 2-sided P-value <0.05 was considered statistically significant. All statistical analyses were implemented in R 3.2.2 (R Foundation for Statistical Computing).
RESULTS
Cohort Characteristics
With a data cutoff of March 2015, 56 patients identified met the inclusion criteria. Many patients were excluded because outside CT imaging was not routinely uploaded until 2008. Two patients were excluded because they had a pathologic complete response with neoadjuvant therapy for a final sample of 54 patients. The cases spanned a period of 14.4 years (September 2000 to February 2015). The median time between CT imaging and surgery was 27 days. The cohort had predominantly early pathologic stage disease as defined by both TNM and Masaoka-Koga stage (Table 2 ). However, there was stage migration to earlier stage disease with the newly defined TNM staging system. The most common WHO subtypes were AB and B2. Some CT characteristics were poorly represented (< 10%) including mediastinal lymph node enlargement, elevated *Other includes 2 pure red cell aplasia and 1 each of acromegaly and hypogammaglobulinemia.
†Other includes 7 thoracoscopies and 1 each of partial median sternotomy, thoracotomy, cervical approach, partial median sternotomy and thoracotomy, and thoracoscopic and cervical approach.
‡Two received chemoradiation. §All incomplete resections occurred in TNM or Masaoka-Koga ≥ stage III disease.
∥WHO type A also includes 2 micronodular thymomas. Two B3 thymomas were of mixed histology. One thymic carcinoma had a minor component of B3. Only 1 NETT.
¶Of the 5 IVA, 2 had N1 and 3 had M1a. Of the 2 IVB, both had N2 disease.
NETT indicates neuroendocrine tumor of thymus.
hemidiaphragm, and pleural effusion ( 
CT Features Associated With Pathologic TNM Stage and Masaoka-Koga Stage
There was an almost perfect correlation between pathologic TNM and Masaoka-Koga stage in this cohort (correlation coefficient, 0.95). The CT features associated with higher pathologic TNM and Masaoka-Koga stage (P < 0.05) in a univariate analysis included lobulated contour, infiltration of mediastinal fat, invasion of adjacent mediastinal structures, vascular endoluminal invasion, and elevated hemidiaphragm (Table 3) . In a multivariate analysis, a predictive score using the following characteristics was associated with higher TNM stage (from highest to lowest weight): elevated hemidiaphragm = vascular endoluminal invasion, pleural nodule, lobulated contour, and heterogeneous internal density (Table 4) . A predictive score associated with higher Masaoka-Koga stage included the following (from highest to lowest weight): elevated hemidiaphragm, vascular endoluminal invasion, and lobulated contour ( Table 4 ). The area under the receiver operating characteristic curve for these predictive scores ranged from 0.76 to 0.79, but the curves were unstable because of small patient numbers, and a threshold with reliable sensitivity and specificity cannot be reported. Figure 1 is an example of CT features of an early stage (A) and advanced stage (B) TET. CT characteristics were also examined in association with the T stage of TNM staging (Tables 3 and 4) . 
Event-free Survival and Overall Survival
When classifying stage by invasive versus non-invasive disease, the survival curves of TNM stage I versus II-IV and Masaoka-Koga stages I-II versus III-IV perfectly overlapped, as expected. Although there were only 14 events in total, the event-free survival was significantly shorter in the higher stage group (hazard ratio, 9.49; 95% confidence interval, 2.11-42.67; P = 0.0003) (Fig. 2A) . For overall survival, deaths only occurred in the higher stage group (Fig. 2B ). We were unable to correlate CT characteristics with clinical outcomes because of the low number of survival events. Table 3 , and WHO subgroup survival curves are reported in Figure 1 
CT Features Associated With WHO Histology and Resection Status
DISCUSSION
CT is the gold standard diagnostic for patients with prevascular mediastinal masses suspicious for TETs. 10, 11 Despite the improved sensitivity of CT, detecting invasion can be challenging. Therefore, we retrospectively examined our institution's cohort of patients with TETs using ITMIG standard report terms to identify preoperative CT characteristics associated with pathologic staging, both the official IASLC/ITMIG TNM (TNM) staging system, which has been incorporated into the 2017 eighth edition AJCC/UICC staging manuals, and the Masaoka-Koga staging system. 15 Masaoka-Koga stage is a strong independent prognostic factor for TETs, and the TNM staging system will continue to be validated as a prognostic factor with future use. 6, 17 The need to determine stage preoperatively is evident in our cohort, as pathologic stage was associated with important preoperative management decisions including performance of pretreatment biopsy and administration of neoadjuvant chemotherapy (Table 3 , Supplemental Digital Content 1, http://links.lww.com/JTI/A93). Although the rate of pretreatment biopsy was relatively high in our cohort, with many being performed at outside institutions before referral, a significantly higher percentage were performed in those with pathologically invasive disease. There was an almost perfect correlation between TNM stage and Masaoka-Koga stage in our cohort, which is expected, given that TNM staging is derived from MasaokaKoga staging (Table 1) . 5 We performed 2 analyses including a proportional odds regression model to assess the association of each individual CT characteristic with hierarchical stage (Table 3) and also a Lasso-regularized multivariate model incorporating all CT characteristics to create a predictive score for stage that adds weights to each characteristic depending on its importance in prediction ( Table 4 ). The predictive score for TNM stage was heavily weighted for clearly invasive or metastatic features of vascular endoluminal invasion, elevated hemidiaphragm, and pleural nodule but also included features of lobulated contour and heterogeneous internal density. The predictive score for MasaokaKoga stage was also heavily weighted for clearly invasive features of elevated hemidiaphragm and vascular endoluminal invasion but also included the feature of lobulated contour. Because of the small sample size of our cohort, these scores had unstable receiver operating characteristics and need to be validated in a larger independent cohort.
It is not surprising that clearly invasive CT features of vascular endoluminal invasion 13, 18 and elevated hemidiaphragm were associated with higher stage (both TNM and Masaoka-Koga). In addition, we confirmed prior reports in the literature of CT features that are not clearly invasive and that are associated with higher stage, including lobulated contour (both TNM and Masaoka-Koga), 12, 13, [18] [19] [20] [21] heterogeneous internal density (TNM), 12, [20] [21] [22] and infiltration of mediastinal fat (T stage). 12, 13, 18 We were unable to confirm prior studies that have found larger size 12, 13, [19] [20] [21] [22] and calcification 12, 18, 21, 22 to be associated with higher stage. In a similar study by Marom et al 12 of 99 patients with thymoma, CT characteristics of both the primary tumor and distant disease independently associated with Masaoka stages III to IV disease in a multivariate model included pleural nodularity and tumor size ( ≥ 7 cm).
Individual CT characteristics have limitations with regard to detecting early invasion. Qu et al 20 reported discrepancies between CT stage formulated on the basis of imaging and pathologic Masaoka-Koga staging when there was tumor involvement of fat and blood vessels. Other studies have reported that for determining invasion, there is limited utility in examining CT for loss or obliteration of fat plane 22 or for infiltration of mediastinal structures along with poor visualization of infiltration into the pleura and lung. 21 Therefore, a predictive score of several CT features, including those that are not clearly invasive, may be more useful in determining pathologic stage. For example, in a study by Tomiyama et al, 21 of 50 patients with thymoma, the combination of 3 CT characteristics distinguished noninvasive from invasive thymoma: lobulated contour, cystic or necrotic portion, and multifocal calcification. Despite active study, there are currently no preoperative imaging scores used in standard practice to determine staging of any tumor type. 23, 24 We also examined preoperative CT characteristics and their association with other prognostic factors of resection status and WHO histology (Table 3) , but the small sample size limited a multivariate analysis.
We have the expected limitations of a retrospective study. First, with regard to staging, (i) mediastinal pleural involvement is difficult to identify retrospectively and was rarely reported in pathology reports, and (ii) lymph node sampling is not routinely performed for early stage TETs; hence assumptions for nodal status were necessary. However, we can expect an almost perfect interobserver agreement between pathologists for Masaoka and TNM staging from the literature. 25 There is also selection bias in our cohort, as we only included patients who underwent a surgical resection. Second, we had a heterogeneous cohort, including patients with thymomas and more aggressive thymic carcinomas. Although all thymic carcinoma cases in our cohort had invasive disease, there were also 10 representative thymomas with invasive disease. We also included patients who received neoadjuvant chemotherapy, but we accounted for this by reviewing the restaging CT scan. Third, we had a relatively small sample size. Therefore, the CT imaging-based predictive score was essentially limited to distinguishing between noninvasive and invasive disease. Arguably, this may be the most important distinction for preoperative management of these tumors. However, we were unable to specifically discern Masaoka-Koga stage III disease and TNM stages II-IIIB disease wherein CT findings may be subtler. Such a predictive scoring system may also be useful in determining when to pursue more sensitive imaging for invasion such as magnetic resonance imaging when invasion is not seen or equivocal on CT. 26 Finally, we only had 1 chest radiologist evaluate the CT imaging, although he was blinded to clinicopathologic data. In previous studies with ≥ 2 radiologists, decision making for discrepancies was frequently based on consensus. 13 Only Tomiyama et al 27 reported that there was relatively high agreement for 2 radiologists (83% to 96%) for specific CT features, and, in another Tomiyama et al 21 study, the kappa statistic for agreement was good (0.77) when radiologists felt confident of their findings. Because of a high percentage of outside imaging studies, there was no standard CT protocol, but slice thickness was reasonable, 18, 28 and contrast was administered in the majority of cases. In the 13% of cases wherein contrast was not administered, we were limited in our ability to evaluate the heterogeneity of the tumor. Some patients in this cohort also had alternative imaging studies, including magnetic resonance imaging and positron emission tomography scan, which may have affected the decision to proceed with surgical resection.
In conclusion, to our knowledge, we are the first to identify a CT imaging-based predictive score for the official IASLC/ITMIG TNM stage incorporated into the eighth edition AJCC/UICC staging manuals for TETs. The score is clearly exploratory given the limitations of our cohort, but it highlights a potentially useful approach in diseases such as TETs wherein CT imaging is critical in management of the disease. The ability of this score in ranking patients according to their risk for higher stage disease needs to be validated in a larger independent cohort.
